Tin tức & Cập nhật

A modified dual therapy as first-line treatment for H. pylori infection demonstrates equal efficacy and compliance relative to recommended regimens, reveals a study. Moreover, a generally modified dual therapy has fewer side effects.

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.

Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.